The Washington Post @washingtonpost
The data from Pfizer has not yet been published or peer reviewed. But it offers a glimmer of good news in the middle of a brutal and early RSV season that has contributed to a wave of respiratory illness that is overwhelming many pediatric hospitals. https://t.co/cwrQcnh6DU — PolitiTweet.org